Table 4.

Initiation of advanced and other therapies (17–21)

No.	Statement	Agreement (%)
17	Access to biologic therapies for patient (when indicated) is fundamental to improving outcomes in severe asthma in Canada	97
18	The choice of biologic therapies should be driven by phenotyping, which includes clinical history (e.g., triggers, age of onset), comorbidities, biomarkers and spirometry	100
19	Future Canadian severe asthma guidelines should include pragmatic and practical guidance on the initiation and choice of biologic therapies for severe asthma	97
20	Once a patient has been approved for an advanced therapy, initiation of treatment should not be delayed by more than 2 weeks	90
21	Once a patient has been approved for an advanced therapy, initiation of treatment should not be delayed by more than 4 weeks	91